

Number of shares and votes in Medivir AB on September 30, 2026

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announces that the number of ordinary shares, class C-shares and votes in Medivir has changed during September 2026 as a result of the conversion of 142,365 class C-shares to ordinary shares. The conversion has been carried out as a part of the delivery of shares in the company's incentive program LTIP 2023.

As of 30 September 2026, the last trading day of the month, the total number of shares in Medivir amounts to 626,487,237, of which 624,179,439 are ordinary shares and 2,307,798 are class C-shares. The total number of votes amounts to 624,410,218.8. Each ordinary share carries one (1) vote and each class C-share carries one tenth (1/10) of a vote.

For additional information, please contact:

Jens Lindberg, CEO, Medivir AB
Telephone: +46 8 5468 3100
Email: jens.lindberg@medivir.com

About Medivir

Medivir develops innovative therapies targeting diseases with high unmet medical need. The company's drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir's two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (Brittle bone disease) and Legg-Calvé-Perthes disease (Perthes disease). Both candidates have blockbuster potential, representing significant value creation opportunities Medivir's shareholders. Collaborations play a key role in Medivir's business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com

This information is information that Medivir is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-09-30 22:15 CEST.